Literature DB >> 28992456

Prediction of new chromene-based inhibitors of tubulin using structure-based virtual screening and molecular dynamics simulation methods.

Hassan Aryapour1, Maryam Dehdab2, Farzin Sohraby3, Afshar Bargahi4.   

Abstract

Multidrug resistance (MDR) is one of the serious problems in cancer research that causes failure in chemotherapy. Chromene-based compounds have been proven to be the novel anti-MDR agents for inhibiting proliferation of tumor cells through tubulin polymerization inhibition of by binding at the colchicine binding site. In this study, we screened a chromene-based database of small molecules using physicochemical, ADMET properties and molecular docking to identify potential hit compounds. In order to validate our hit compounds, molecular dynamics simulations and related analysis were carried out and the results suggest that our hit compounds (PubChem CIDs: 16814409, 17594471, 57367244 and 69899719) can prove to be potential inhibitors of tubulin. The in silico results show that the present hits, like colchicine, effectively suppressed the dynamic instability of microtubules and induced microtubule-depolymerization and cell cycle arrest.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cancer; Chromene; Docking; Microtubule; Molecular dynamics simulation; Tubulin; Virtual screening

Mesh:

Substances:

Year:  2017        PMID: 28992456     DOI: 10.1016/j.compbiolchem.2017.09.007

Source DB:  PubMed          Journal:  Comput Biol Chem        ISSN: 1476-9271            Impact factor:   2.877


  2 in total

1.  In Silico Exploration of Novel Tubulin Inhibitors: A Combination of Docking and Molecular Dynamics Simulations, Pharmacophore Modeling, and Virtual Screening.

Authors:  Farzin Hadizadeh; Razieh Ghodsi; Salimeh Mirzaei; Amirhossein Sahebkar
Journal:  Comput Math Methods Med       Date:  2022-01-15       Impact factor: 2.238

2.  In silico Investigations of the Mode of Action of Novel Colchicine Derivatives Targeting β-Tubulin Isotypes: A Search for a Selective and Specific β-III Tubulin Ligand.

Authors:  Lorenzo Pallante; Antonio Rocca; Greta Klejborowska; Adam Huczynski; Gianvito Grasso; Jack A Tuszynski; Marco A Deriu
Journal:  Front Chem       Date:  2020-02-21       Impact factor: 5.221

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.